Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement

09-Jun-2010 - France

Cellectis bioresearch, subsidiary of Cellectis, and Lonza announced that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.

Cellectis bioresearch will use its meganucleases to deactivate (knock-out) the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line. Meganucleases are molecular scissors that can be directed to a single highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene function.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances